Most investors agreed that the technology sector remains relatively resilient to the disruption caused by the global pandemic, although B2B software companies are likely to experience different implications based on the exposure of the end-market they are serving.
HGGC sees opportunities to back dislocated assets in the public markets and also eyes win-win partnership transactions.
While Varma is supportive of a shutdown, he said the medical damage to patients with other diseases is going to become insurmountable.
As one of few to lock down financing amidst the covid-19 turmoil, the PE firm’s specialty materials company Kymera manages to clinch a sizable add-on.
The turnaround expert shares his take on covid-19’s impact on PE, asserting that he’s seeing MAC clauses implemented for the first time in his 20-year career.
Imprivata, which helps healthcare providers protect patient information, was anticipated to command upwards of $2bn in a potential sale.
As the JPM and Rothschild process for the French nuclear medicine company is put on hold, attention shifts to Webster Equity-backed PharmaLogic, sources told PE Hub.